Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 19/20 | 1.00 |
| ▸ | CDC42BPB | Q9Y5S2 | 19/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 18/20 | 1.00 |
| ▸ | CDC42BPA | Q5VT25 | 5/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29869707 | 1.00 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPAUSP2 | |
| SCHEMBL29869785 | 0.86 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL30668732 | 0.86 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24672139 | 0.86 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24673288 | 0.86 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24672965 | 0.86 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL29869292 | 0.85 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24672478 | 0.85 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL24672477 | 0.82 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL30668726 | 0.82 | ROCK1 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | PDXK, CCNK, CDC42BPB | ROCK1 1054/4885CDC42BPB 3/4885ROCK2 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.